Overview

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Olodaterol